Affiliations: [a] Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA | [b] Barrow Neurological Institute, Phoenix, AZ, USA | [c] Department of Microbiology and Immunology, Columbia University, New York, NY, USA | [d] Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA
Correspondence:
[*]
Correspondence to: Kalipada Pahan, PhD, Department of Neurological Sciences, Rush University Medical Center, 1735 West Harrison St, Suite 320, Chicago, IL 60612, USA. Tel.: +1 312 563 3592; Fax: +1 312 563 3571; Kalipada_Pahan@rush.edu
Abstract: Alzheimer’s disease (AD) is the most common form of dementia. Despite intense investigations, no effective therapy is available to halt its progression. We found that NF-κB was activated within the hippocampus and cortex of AD subjects and that activated forms of NF-κB negatively correlated with cognitive function monitored by Mini-Mental State Examination and global cognitive z score. Accordingly, NF-κB activation was also observed in the hippocampus of a transgenic (5XFAD) mouse model of AD. It has been shown that peptides corresponding to the NF-κB essential modifier (NEMO)-binding domain (NBD) of IκB kinase α (IKKα) or IκB kinase β (IKKβ) specifically inhibit the induction of NF-κB activation without inhibiting the basal NF-κB activity. Interestingly, after intranasal administration, wild-type NBD peptide entered into the hippocampus, reduced hippocampal activation of NF-κB, suppressed hippocampal microglial activation, lowered the burden of Aβ in the hippocampus, attenuated apoptosis of hippocampal neurons, protected plasticity-related molecules, and improved memory and learning in 5XFAD mice. Mutated NBD peptide had no such protective effect, indicating the specificity of our finding. These results suggest that selective targeting of NF-κB activation by intranasal administration of NBD peptide may be of therapeutic benefit for AD patients.
